|
1
|
No authors listed. WORLD Health
Organization. Cancer registration and statistics. J Am Med Womens
Assoc. 6(142)1951.PubMed/NCBI
|
|
2
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yoon HH, Bendell JC, Braiteh FS, Firdaus
I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz
JD, et al: Ramucirumab combined with FOLFOX as front-line therapy
for advanced esophageal, gastroesophageal junction, or gastric
adenocarcinoma: A randomized, double-blind, multicenter phase II
trial. Ann Oncol. 27:2196–2203. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2018 (5th edition).
Gastric Cancer. 24:1–21. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kato K, Satoh T, Muro K, Yoshikawa T,
Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, et
al: A subanalysis of Japanese patients in a randomized,
double-blind, placebo-controlled, phase 3 trial of nivolumab for
patients with advanced gastric or gastro-esophageal junction cancer
refractory to, or intolerant of, at least two previous chemotherapy
regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 22:344–354.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC,
Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al:
Nivolumab plus chemotherapy versus placebo plus chemotherapy in
patients with HER2-negative, untreated, unresectable advanced or
recurrent gastric or gastro-oesophageal junction cancer
(ATTRACTION-4): A randomised, multicentre, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 23:234–247.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus nivolumab in patients with advanced gastric or
colorectal cancer: An open-label, dose-escalation, and
dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol.
38:2053–2061. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Herbst RS, Arkenau HT, Santana-Davila R,
Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG,
Martin-Liberal J, et al: Ramucirumab plus pembrolizumab in patients
with previously treated advanced non-small-cell lung cancer,
gastro-oesophageal cancer, or urothelial carcinomas (JVDF): A
multicohort, non-randomised, open-label, phase 1a/b trial. Lancet
Oncol. 20:1109–1123. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kim J, Byeon S, Kim H, Yeo JH, Hong JY,
Lee J, Lim HY, Kang WK and Kim ST: Impact of prior ramucirumab use
on treatment outcomes of checkpoint inhibitors in advanced gastric
cancer patients. Targeted Oncol. 15:203–209. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ohm JE, Gabrilovich DI, Sempowski GD,
Kisseleva E, Parman KS, Nadaf S and Carbone DP: VEGF inhibits
T-cell development and may contribute to tumor-induced immune
suppression. Blood. 101:4878–4886. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tada Y, Togashi Y, Kotani D, Kuwata T,
Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H and Shitara K:
Targeting VEGFR2 with Ramucirumab strongly impacts
effector/activated regulatory T cells and CD8+ T cells
in the tumor microenvironment. J Immunother Cancer.
6(106)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Voron T, Colussi O, Marcheteau E, Pernot
S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N,
Tanchot C, et al: VEGF-A modulates expression of inhibitory
checkpoints on CD8+ T cells in tumors. J Exp Med. 212:139–148.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nakajima TE, Kadowaki S, Minashi K,
Nishina T, Yamanaka T, Hayashi Y, Izawa N, Muro K, Hironaka S,
Kajiwara T and Kawakami Y: Multicenter phase I/II study of
nivolumab combined with paclitaxel plus ramucirumab as second-line
treatment in patients with advanced gastric cancer. Clin Cancer
Res. 27:1029–1036. 2021.PubMed/NCBI View Article : Google Scholar
|
